1 / 15

Rubella Jóhann M. Hauksson

Rubella Jóhann M. Hauksson. Vírusinn. Togavirus Aðeins til í manninum Enveloped ssRNA Þrjú prótein C: capside sem umlykur RNA E1, E2: transmembrane spikes Festist sennilega við phospho- og glycolipids frumuhimnunnar Fjölgun á innanfrumuhimnum

temple
Télécharger la présentation

Rubella Jóhann M. Hauksson

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Rubella Jóhann M. Hauksson

  2. Vírusinn • Togavirus • Aðeins til í manninum • Enveloped • ssRNA • Þrjú prótein • C: capside sem umlykur RNA • E1, E2: transmembrane spikes • Festist sennilega við phospho- og glycolipids frumuhimnunnar • Fjölgun • á innanfrumuhimnum • E1 er nauðsynlegt til að vírusinn komist út

  3. Úðasmit Úbreyðsla um líkamann nasopharynx eitlar ... Fjölgun á innanfrumuhimnum í cytoplasma Finnst í blóði 5-7 dögum e. smit Kemst yfir fylgju Skemmdir með apoptosu Smithætta : mest 2 vikur fyrir útbrot minnkar þegar útbrot koma neutralizing antibodies Smit

  4. Hiti, 38°C Eitlastækkanir post-auricular og sub-occipital geta haldist í viku Rash erythematous, maculopapular andlit → búkur → limir nokkrir dagar Forchheimer’s sign 20% tilfella papulur á soft palate Arthritis Thrombocytopenia Encephalitis Gamlir Ungir Ófæddir CRS Einkenni

  5. Getur valdið abortion 20% á 1. trimestri of létt barn Líffæri <8 vikur augu retinopathy cataract microphthalmia hjarta pulmonary stenosis PDA VSD <16 vikur heyrnarleysi, sensorineural CNS mental retardation microcephaly meningoencephalitis Þróast síðar á ævinni DM, 40% encephalopathy Intrauterine sýking Congenital Rubella Syndrome

  6. Meðferð Sýking fæddra Paracetamol RCS einkennameðferð Horfur Sýking fæddra góðar horfur RCS slæmar horfur

  7. Bólusetning lifandi veiklaður vírus MMR Tvær sprautur Nöfn MMR II Priorix Trimovax Rubella útrýmt Kúba, 1990s USA, 2004 Hjarðónæmi hjarðónæmis þröskuldur 80-85% Deilur um MMR Forvarnir

  8. Faraldrar • Major epidemics • 10-30 ára fresti • Faraldur USA 1964 • 500 þús. veiktust • 20 þús. með RCS • 2.200 dóu • Minor epidemics • 7-9 ára fresti

  9. Stuðlar MMR að einhverfu? • Andrew Wakefield et al. 1998 í Lancet • MMR – einhverfa – meltingarfærasjúkdómar • 12 sjúklingar • “autistic enterocolitis” • 2003, könnun meðal lækna í Bretlandi • 77% mundu gefa MMR barni sem hefði fjölskyldusögu um autism • 3% héldu að MMR gæti stundum valdið autism • 2004, samskonar könnun • 82% mundu gefa MMR barni sem hefði fjölskyldusögu um autism • 2% héldu að MMR gæti stundum valdið autism

  10. Wakefield • Málshöfðun gegn framleiðindum MMR • 400 þús. pund frá lögfræðingum • greiðslur hófust 1996 • Brian Deer í The Sunday Times, 2006 • nokkrir foreldrar voru þátttakendur í málaferlunum • Hafði sótt um einkaleyfi á bóluefni • í samkeppni við MMR • single vacine • bólusett fyrir einum sjúkdómi í einu

  11. MMR og autism í Japan • Byrjað að nota MMR árið 1989 en hætt 1993. Aðeins notuð single vaccines þaðan í frá. • Rannsókn árið 2005 á yfir 30,000 börnum fæddum í Yokohama. • "The incidence of all autistic spectrum disorders (ASD), and of autism, continued to rise after MMR vaccine was discontinued. The incidence of autism was higher in children born after 1992 who were not vaccinated with MMR than in children born before 1992 who were vaccinated. The incidence of autism associated with regression was the same during the use of MMR and after it was discontinued." • "The significance of this finding is that MMR vaccination is most unlikely to be a main cause of ASD, that it cannot explain the rise over time in the incidence of ASD, and that withdrawal of MMR in countries where it is still being used cannot be expected to lead to a reduction in the incidence of ASD." • Honda H, Shimizu Y, Rutter M (2005). "No effect of MMR withdrawal on the incidence of autism: a total population study". J Child Psychol Psychiatry 46 (6): 572–9.

More Related